Gene therapy for prostate cancer

被引：2
作者：
Gingrich J.R. [1 ]
Chauhan R.D. [1 ]
Steiner M.S. [1 ]
机构：
[1] Department of Urology, University of Tennessee Medical Center, 956 Court Avenue, H216, Memphis, 38163, TN
来源：
Current Oncology Reports | 2001年 / 3卷 / 5期
关键词：
Cytosine Deaminase; Gene Therapy; Herpes Simplex Virus Thymidine Kinase; Prostate Cancer; Radical Prostatectomy;
D O I：
10.1007/s11912-001-0031-6
中图分类号：
学科分类号：
摘要：
Basic research continues to unravel the molecular complexity of normal and abnormal biologic processes. The development of means to affect the expression level of genes that promote or contribute to cellular transformation, invasion, and metastasis has spawned the concept of gene therapy. This relatively new field seeks to reverse or suspend the pathologic progression of a variety of diseases including the malignant transformation of prostatic epithelial cells. Initial clinical trials for prostate cancer have thus far shown gene therapy to be relatively safe, although definitive evidence of durable therapeutic efficacy remains to be demonstrated. In this article, recent preclinical research, current therapeutic strategies, and recent results of gene therapy clinical trials for the treatment of prostate cancer are reviewed. © 2001, Current Science Inc.
引用
收藏
页码：438 / 447
页数：9
相关论文
共 58 条
[31]  
Steiner M.S., Anthony C.T., Lu Y., Et al., Antisense c-myc retroviral vector suppresses established human prostate cancer, Hum Gene Ther, 9, pp. 747-755, (1998)
[32]  
Kim M., Wright M., Deshane J., Et al., A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow, Hum Gene Ther, 8, pp. 157-170, (1997)
[33]  
Logothetis C.J., Hossan E., Pettaway C.A., Et al., AD-p53 intraprostatic gene therapy preceding radical prostatectomy (RP): An in vivo model for targeted therapy development, AUA 94Th Annual Meeting, (1999)
[34]  
Hall S.J., Mutchnik S.E., Chen S.H., Et al., Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer, Int J Cancer, 70, pp. 183-187, (1997)
[35]  
Eastham J.A., Chen S.H., Sehgal I., Et al., Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models, Hum Gene Ther, 7, pp. 515-523, (1996)
[36]  
Hall S.J., Sanford M.A., Atkinson G., Et al., Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer, Cancer Res, 58, pp. 3221-3225, (1998)
[37]  
Herman J.R., Adler H.L., Aguilar-Cordova E., Et al., In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial, Hum Gene Ther, 10, pp. 1239-1249, (1999)
[38]  
Shalev M., Kadmon D., Teh B.S., Et al., Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer, J Urol, 163, pp. 1747-1750, (2000)
[39]  
Ayala G., Wheeler T.M., Shalev M., Et al., Cytopathic effect of in situ gene therapy in prostate cancer, Hum Pathol, 31, pp. 866-870, (2000)
[40]  
Koeneman K.S., Kao C., Ko S.C., Et al., Osteocalcin-directed gene therapy for prostate-cancer bone metastasis, World J Urol, 18, pp. 102-110, (2000)
123456